Literature DB >> 11014244

Aldosterone: a mediator of myocardial necrosis and renal arteriopathy.

R Rocha1, C T Stier, I Kifor, M R Ochoa-Maya, H G Rennke, G H Williams, G K Adler.   

Abstract

To determine the role of aldosterone in mediating cardiovascular damage, we performed ablation/replacement experiments with aldosterone in a rat model of cardiac injury. Administration of angiotensin II and Nomega-nitro-L-arginine methyl ester (L-NAME; nitric oxide synthesis inhibitor) to male rats drinking 1% saline caused hypertension, severe biventricular myocardial necrosis, proteinuria, and fibrinoid necrosis of renal and cardiac vessels. Removal of aldosterone by adrenalectomy or through administration of the selective aldosterone antagonist eplerenone markedly reduced the cardiac and renal damage without significantly altering blood pressure. Aldosterone infusion in adrenalectomized, glucocorticoid-replaced L-NAME/angiotensin II-treated animals restored damage. Thus, we identified aldosterone as a critical mediator of L-NAME/angiotensin II induced vascular damage through mechanisms apparently independent of its effects on systolic blood pressure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11014244     DOI: 10.1210/endo.141.10.7711

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  99 in total

1.  Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease.

Authors:  Alessia Buglioni; Valentina Cannone; Alessandro Cataliotti; S Jeson Sangaralingham; Denise M Heublein; Christopher G Scott; Kent R Bailey; Richard J Rodeheffer; Paolo Dessì-Fulgheri; Riccardo Sarzani; John C Burnett
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

2.  Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets.

Authors:  J M Luther; P Luo; M T Kreger; M Brissova; C Dai; T T Whitfield; H S Kim; D H Wasserman; A C Powers; N J Brown
Journal:  Diabetologia       Date:  2011-04-26       Impact factor: 10.122

Review 3.  Regression of left ventricular hypertrophy is a key goal of hypertension management.

Authors:  Rubin Zhang; Judy Crump; Efrain Reisin
Journal:  Curr Hypertens Rep       Date:  2003-08       Impact factor: 5.369

Review 4.  Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease.

Authors:  Emmanuel L Bravo
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

Review 5.  Minireview: aldosterone biosynthesis: electrically gated for our protection.

Authors:  Nick A Guagliardo; Junlan Yao; Changlong Hu; Paula Q Barrett
Journal:  Endocrinology       Date:  2012-06-11       Impact factor: 4.736

6.  Classics in Cardiovascular Endocrinology: Aldosterone Action Beyond Electrolytes.

Authors:  Richard J Auchus
Journal:  Endocrinology       Date:  2015-12-23       Impact factor: 4.736

7.  Aldosterone's rapid, nongenomic effects are mediated by striatin: a modulator of aldosterone's effect on estrogen action.

Authors:  Patricia Coutinho; Christopher Vega; Luminita H Pojoga; Alicia Rivera; Gregory N Prado; Tham M Yao; Gail Adler; Manuel Torres-Grajales; Enrique R Maldonado; Arelys Ramos-Rivera; Jonathan S Williams; Gordon Williams; Jose R Romero
Journal:  Endocrinology       Date:  2014-03-21       Impact factor: 4.736

Review 8.  Aldosterone: a risk factor for vascular disease.

Authors:  Mario Fritsch Neves; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2003-02       Impact factor: 5.369

Review 9.  Interaction of aldosterone and extracellular volume in the pathogenesis of obesity-associated kidney disease: a narrative review.

Authors:  Andrew S Bomback; Philip J Klemmer
Journal:  Am J Nephrol       Date:  2009-03-20       Impact factor: 3.754

Review 10.  Mineralocorticoid receptor antagonists and hypertension: is there a rationale?

Authors:  Olga Gumieniak; Gordon H Williams
Journal:  Curr Hypertens Rep       Date:  2004-08       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.